CAGE 01SC8 - CHILDREN'S HOSPITAL MEDICAL CENTER
USA

CHILDREN'S HOSPITAL MEDICAL CENTER

DBA CHILDREN'S HOME HEALTHCARE

CAGE Code: 01SC8
DUNS: 071284913
3333 BURNET AVE
CINCINNATI OH 45229-3026
UNITED STATES

Telephone: 5136366633
Fax: 5136361392

CHILDREN'S HOSPITAL MEDICAL CENTER, DBA CHILDREN'S HOME HEALTHCARE is an Active Commercial Supplier with the Cage Code 01SC8 and is tracked by Dun & Bradstreet under DUNS Number 071284913.

Additional Data For CAGE 01SC8

SIC Code 1:8011
Status:A
Type:F
Size:E
Primary Business:N
Type of Business:N
Woman Owned:N
CAO:S3605A
ADP CNT CT:HQ0337

USA Government Contracting Activity for 01SC8

Thursday, December 21, 2017
$0.00
7500: Department of Health and Human Services
75N910: NIH NCI

B: PURCHASE ORDER
IGF::OT::IGF NO-COST EXTENSION. THE CONTRACTOR SHALL PRODUCE 20 LITERS OF CLINICAL-GRADE GAMMA-RETROVIRAL GENE-THERAPY VECTOR FOR USE IN A CLINICAL TRIAL.
6505: DRUGS AND BIOLOGICALS

  HHSN261201700263P     N02RC7253688  
Thursday, December 21, 2017
$0.00
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

C: DELIVERY ORDER
PURPOSE: TO REVISE ARTICLE G.2. KEY PERSONNEL AND ADD DR. RHONDA CARDIN AS THE CO-PRINCIPAL INVESTIGATOR.
AN11: R&D- MEDICAL: BIOMEDICAL (BASIC RESEARCH)

  HHSN27200003     HHSN272201700017I     NIHAI2016059  
Thursday, December 14, 2017
$0.00
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

C: DELIVERY ORDER
IGF::OT::IGF; VTEU PROTOCOL SUB-STUDIES: PROTOCOL DEVELOPMENT, IMPLEMENTATION AND ASSAYS, PROTOCOL 16-0006 POP 09/20/2015 TO 06/30/2018
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200007     HHSN272201300016I     NIAIDDMIDNIHAI2012144  
Wednesday, November 22, 2017
($0.23)
7500: Department of Health and Human Services
75N940: NATIONAL INSTITUTES OF HEALTH NICHD

D: DEFINITIVE CONTRACT
IGF::OT::IGF MAINTENANCE, ANALYSIS AND DISSEMINATION OF CMIND DATABASE
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN275201400002C  
Wednesday, November 1, 2017
$736,623.00
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

C: DELIVERY ORDER
TO ISSUE TASK ORDER A-05, "MOUSE AND GUINEA PIG MODELS FOR CYTOMEGALOVIRUS AND HERPES SIMPLEX VIRUSES."
AN11: R&D- MEDICAL: BIOMEDICAL (BASIC RESEARCH)

  HHSN27200003     HHSN272201700017I     NIHAI2016059  
Thursday, October 19, 2017
$5,433.00
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

C: DELIVERY ORDER
PURPOSE: TO ISSUE TASK A-08 IN THE AMOUNT OF $5,433 FOR THE "BASE IDIQ KICK-OFF MEETING."
AN11: R&D- MEDICAL: BIOMEDICAL (BASIC RESEARCH)

  HHSN27200002     HHSN272201700017I     NIHAI2016059  
Thursday, September 28, 2017
($0.06)
7500: Department of Health and Human Services
75D301: CDC OFFICE OF ACQUISITION SERVICES

C: DELIVERY ORDER
IGF::OT::IGF CISA CHILDERN'S HOSPITAL MEDICAL CENTER
R499: SUPPORT- PROFESSIONAL: OTHER

  HHSD2002012536610003     HHSD200201253661I  
Saturday, September 23, 2017
$39,143.00
7500: Department of Health and Human Services
75D301: CDC OFFICE OF ACQUISITION SERVICES

C: DELIVERY ORDER
IGF::OT::IGF CISA CHILDERN'S HOSPITAL MEDICAL CENTER
R499: SUPPORT- PROFESSIONAL: OTHER

  HHSD2002012536610008     HHSD200201253661I  
Thursday, September 21, 2017
$1,324,403.00
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

C: DELIVERY ORDER
IGF::OT::IGF VACCINE AND TREATMENT EVALUATION UNITS (VTEU) OVERALL ADMINISTRATION, CLINICAL OPERATIONS SUPPORT AND CONCEPT AND PROTOCOL DEVELOPMENT, IMPLEMENTATION AND ASSAYS TASK AREA A-D TASK ORDER FY.2018.A1B1C1D1.0077
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200014     HHSN272201300016I     NIAIDDMIDNIHAI2012144  
Wednesday, September 20, 2017
$124,847.00
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

C: DELIVERY ORDER
IGF::OT::IGF VACCINE AND TREATMENT EVALUATION UNITS (VTEU) ASSAY TASK AREA D PHASE 1 VACCINE TRIAL FOR RSV TASK ORDER 16-0108.D1.0084
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200017     HHSN272201300016I     NIAIDDMIDNIHAI2012144  
Tuesday, September 19, 2017
$104,180.00
7500: Department of Health and Human Services
75D301: CDC OFFICE OF ACQUISITION SERVICES

C: DELIVERY ORDER
IGF::OT::IGF CISA CHILDERN'S HOSPITAL MEDICAL CENTER
R499: SUPPORT- PROFESSIONAL: OTHER

  HHSD2002012536610007     HHSD200201253661I  
Monday, September 18, 2017
$146,341.00
7500: Department of Health and Human Services
75D301: CDC OFFICE OF ACQUISITION SERVICES

C: DELIVERY ORDER
IGF::OT::IGF CISA CHILDERN'S HOSPITAL MEDICAL CENTER TDAP CONTRIBUTING
R499: SUPPORT- PROFESSIONAL: OTHER

  HHSD2002012536610009     HHSD200201253661I  
Friday, September 15, 2017
$289,680.44
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

C: DELIVERY ORDER
IGF::OT::IGF VACCINE AND TREATMENT EVALUATION UNITS, A PHASE I RANDOMIZED, DOUBLE-BLIND, CONTROLLED TRIAL IN HEALTHY ADULTS TO ASSESS THE SAFETY, REACTOGENICITY, AND IMMUNOGENICITY OF A MONOVALENT INACTIVATED INFLUENZA A/H5N8 VIRUS VACCINE ADMINISTERED INTRAMUSCULARLY GIVEN WITH OR WITHOUT AS03 OR MF59
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200011     HHSN272201300016I     NIAIDDMIDNIHAI2012144  
Thursday, August 31, 2017
$0.00
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

C: DELIVERY ORDER
IGF::OT::IGF 1300016I TO 0008-15-0064.C1.0039 INFLUENZA A/H5N8 VIRUS VACCINE TRIAL; BIOD CAN 8470038; $617,036 POP 10/19/2015 THROUGH 06/30/2018
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200008     HHSN272201300016I     NIAIDDMIDNIHAI2012144  
Wednesday, August 30, 2017
$0.00
7500: Department of Health and Human Services
75D301: CDC OFFICE OF ACQUISITION SERVICES

C: DELIVERY ORDER
IGF::OT::IGF CISA CHILDERN'S HOSPITAL MEDICAL CENTER
AN46: R&D- MEDICAL: HEALTH SERVICES (MANAGEMENT/SUPPORT)

  HHSD2002012536610004     HHSD200201253661I  
Friday, August 18, 2017
$2,927,513.00
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

C: DELIVERY ORDER
IGF::OT::IGF VACCINE AND TREATMENT EVALUATION UNITS (VTEU)PROTOCOL DEVELOPMENT, IMPLEMENTATION AND ASSAYSTASK AREA B-D PHASE 1 VACCINE TRIAL FOR EBOLA VIRUS TASK ORDER 14-0092.B1C1D1.0061
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200016     HHSN272201300016I     NIAIDDMIDNIHAI2012144  
Friday, August 11, 2017
$258,310.00
7500: Department of Health and Human Services
75N910: NIH NCI

B: PURCHASE ORDER
IGF::OT::IGF THE CONTRACTOR SHALL PRODUCE 20 LITERS OF CLINICAL-GRADE GAMMA-RETROVIRAL GENE-THERAPY VECTOR FOR USE IN A CLINICAL TRIAL. THIS GAMMA-RETROVIRAL GENE-THERAPY VECTOR WILL BE PRODUCED BY THE TRANSIENT TRANSFECTION METHOD, AND THE VECTOR MUST BE COMPLETED BY THE END OF 2017. THE VECTOR WILL ENCODE A CHIMERIC ANTIGEN RECEPTOR (CAR) RECOGNIZING A MULTIPLE MYELOMA ANTIGEN. THE INTENDED USE OF THIS VECTOR IS TO TRANSDUCE PATIENT T CELLS. THESE T CELLS WILL BE ADMINISTERED AS A TREATMENT FOR MULTIPLE MYELOMA IN A CLINICAL TRIAL. THE VECTOR WILL BE GIBBON APE LEUKEMIA VIRUS (GALV) PSEUDOTYPED. THE VECTOR WILL BE GENERATED IN 293T CELLS. THE CONTRACTOR WILL PROVIDE PACKAGING PLASMIDS. THE NCI WILL PROVIDE A PLASMID ENCODING THE CAR ALSO KNOWN AS THE EXPRESSION CONSTRUCT.
6505: DRUGS AND BIOLOGICALS

  HHSN261201700263P     N02RC7253688  
Wednesday, July 26, 2017
$5,583,665.00
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

C: DELIVERY ORDER
IGF::OT::IGF VACCINE AND TREATMENT EVALUATION UNITS (VTEU) PROTOCOL DEVELOPMENT AND IMPLEMENTATION TASK AREA B-C PHASE II VACCINE TRIAL FOR INFLUENZA TASK ORDER
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200015     HHSN272201300016I     NIAIDDMIDNIHAI2012144  
Thursday, July 13, 2017
$0.00
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

B: IDC
IGF::OT::IGF PRE-CLINICAL MODELS OF INFECTIOUS DISEASES
AN11: R&D- MEDICAL: BIOMEDICAL (BASIC RESEARCH)

  HHSN272201700017I     NIHAI2016059  
Wednesday, July 12, 2017
$297,665.00
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

C: DELIVERY ORDER
IGF::OT::IGF AWARD OF VACCINE AND TREATMENT EVALUATION UNITS (VTEU)
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200014     HHSN272201300016I     NIAIDDMIDNIHAI2012144  
Monday, July 10, 2017
$2,852,223.83
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

C: DELIVERY ORDER
IGF::OT::IGF AWARD OF VACCINE AND TREATMENT EVALUATION UNITS (VTEU)
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200013     HHSN272201300016I     NIAIDDMIDNIHAI2012144  
Friday, July 7, 2017
($4,847,701.01)
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

D: DEFINITIVE CONTRACT
VACCINE AND EVALUATION TREATMENT UNITS (VTEUS): EVALUATION OF CONTROL MEASURES FOR DISEASES OTHER THAN AIDS. THE PURPOSE OF THIS MODIFICATION IS TO DEOBLIGATE FUNDS ON VARIOUS OPTIONS WHERE WORK HAS BEEN COMPLETED.
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN272200800006C  
Thursday, July 6, 2017
$124,000.00
8000: National Aeronautics and Space Administration
80NSSC: NASA SHARED SERVICES CENTER

G: GRANT FOR RESEARCH
THE SUCCESSFUL DIASPORA OF HUMANS INTO DEEP SPACE REQUIRES AN UNDERSTANDING OF THE RISK OF DEEP SPACE RADIATION EXPOSURE ON SHORT AND LONG TERM HEALTH OUTCOMES, INCLUDING RISKS TO THE CENTRAL NERVOUS SYSTEM (CNS). ASSESSING CNS RISK MUST CONSIDER THE IMPACT OF DEEP SPACE RADIATION ON THE BEHAVIOR OF LATENT NEUROTROPIC INFECTIOUS AGENTS THAT RESIDE WITHIN THE HUMAN CNS. HERPES SIMPLEX VIRUS (HSV) IS AMONG THE MOST WIDESPREAD AGENT IN THIS CATEGORY, PERMANENTLY INFECTING THE NERVOUS SYSTEMS OF MORE THAN 80% OF THE GLOBAL POPULATION. LATENT HSV CANNOT BE ELIMINATED FROM THE NERVOUS SYSTEM AND THERE IS NO VACCINE TO PREVENT INFECTION. THUS FOR THE FORESEEABLE FUTURE, HUMANS TRAVELING INTO DEEP SPACE WILL HARBOR THIS AND OTHER ALPHA-HERPESVIRUSES. WHILE UNCONTROLLED HSV REPLICATION IN THE CNS RESULTS IN OFTEN FATAL ENCEPHALITIS, THIS VIRUS ALSO HAS THE CAPACITY TO PROMOTE CHRONIC INFLAMMATION AND NEURODEGENERATION. INDEED THERE IS SUBSTANTIAL EVIDENCE THAT IN COMBINATION WITH GENETIC RISK FACTORS, HSV INFECTION IN THE CNS FURTHER INCREASES THE PROBABILITY OF DEVELOPING ALZHEIMER S DISEASE. IN THIS PRO-POSAL, THE EFFECTS OF SIMULATED DEEP SPACE RADIATION ON THE DEVELOPMENT OF CNS PATHOLOGY (REACTIVE LESIONS) AND THE IMPACT OF LATENT AND INDUCED IN VIVO REACTIVATION OF HSV INFECTION ON THE DEVELOPMENT OF CNS PATHOLOGY WILL BE DETERMINED TOGETHER WITH THE ROLE THAT HUMAN APOE ALLELES PLAY IN THESE PROCESSES. WE WILL EMPLOY OUR WELL CHARACTERIZED MOUSE MODEL OF HSV LATENCY AND IN VIVO REACTIVATION IN COMBINATION WITH QUANTITATIVE MEASURES OF REACTIVE LESIONS IN THE CNS TO DETERMINE THE EFFECT OF SIMULATED DEEP SPACE RADIATION ON HSV MEDIATED CNS DAMAGE. THE ACUTE STAGE OF INFECTION WILL BE MONITORED USING OUR STANDARD APPROACHES INCLUDING QUANTITATIVE EVALUATION OF INFECTIOUS VIRUS TITERS. LATENT INFECTION IN THE TRIGEMINAL GANGLIA AND BRAIN WILL BE QUANTIFIED AT 30-40 DAYS POSTINFECTION (PI) USING OUR QUANTITATIVE REAL TIME PCR ASSAY FOR THE VIRAL GENOME. SPONTANEOUS AND INDUCED EXIT FROM LATENCY WILL BE QUANTIFIED AT THE SINGLE NEURON LEVEL USING OUR WHOLE TG IMMUNOHISTOCHEMICAL ASSAY. THIS APPROACH PERMITS US TO IDENTIFY EVEN A SINGLE POSITIVE NEURON IN GROUPS OF GANGLIA. VIRAL REACTIVATION (PRODUCTION OF INFECTIOUS VIRUS) WILL BE EVALUATED USING OUR STANDARD ASSAY. REACTIVATION WILL BE INDUCED USING OUR WELL-ESTABLISHED HYPERTHERMIC STRESS PROCEDURE (TEMPERATURE OF THE MICE IS RAISED TO 42.5 C FOR 10 MINUTES). WE HAVE SHOWN AND PUBLISHED THAT THIS PROCEDURE RELIABLY INDUCES VIRAL REACTIVATION AND CAN BE REPEATEDLY EMPLOYED TWO TIMES PER WEEK FOR PERIODS OF UP TO AT LEAST ONE YEAR PI. WE HAVE DETERMINED THE REPEATED REACTIVATION STRESS OF C57BL/6 MICE RESULTS IN REACTIVE ASTROCYTIC LESIONS IN THE CNS OF HSV INFECTED BUT NOT IN UNINFECTED MICE. INTERESTINGLY THIS DAMAGE IS MUCH MORE EXTENSIVE IN MICE THAT EXPRESS THE HUMAN APOE4 ALLELE OR IN IL10 KNOCK OUT MICE. THIS SUGGESTS IMPORTANT RELEVANCE TO HUMAN BIOLOGY SINCE BOTH IL10 POLYMORPHISMS AND THE APOE4 ALLELE HAVE BEEN SHOWN TO BE ASSOCIATED WITH INCREASED RISK OF ACQUIRING ALZHEIMER S DISEASE . WE NOW PROPOSE TO COLLABORATE WITH RADIATION BIOLOGISTS AT NASA TO DETERMINE APPROPRIATE CONDITIONS TO SIMULATE DEEP SPACE RADIATION AND WE WILL QUANTIFY THE EFFECTS OF SUCH RADIATION ON CNS DAMAGE INDUCED BY REACTIVATION OF HSV LATENT INFECTIONS. SIGNIFICANCE: THE GOAL OF NASA S SPACE RADIATION RESEARCH IS TO ENABLE THE HUMAN EXPLORATION OF SPACE WITHIN ACCEPTABLE RISKS FROM SPACE RADIATION. IMPORTANTLY, THE PROPOSED STUDIES WILL DETERMINE THE INTEGRATED RISK OF THE INTERACTION OF GALACTIC COSMIC RADIATION WITH UNINFECTED AND LATENTLY INFECTED CNS. THE PREVALENCE OF HSV INFECTION AMONG HUMANS MAKES THIS A NEARLY UNAVOIDABLE ADDITIONAL FACTOR THAT COULD SIGNIFICANLTY HEIGHTEN THE RISK OF CNS DAMAGE UPON GCR EXPOSURE.
AR21: R&D- SPACE: SCIENCE/APPLICATIONS (BASIC RESEARCH)

  NNX13AO47G  
Tuesday, June 13, 2017
$243,329.00
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

C: DELIVERY ORDER
IGF::OT::IGF A RANDOMIZED TRIAL TO EVALUATE SHORT COURSE VS. STANDARD COURSE OUTPATIENT BETA-LACTAM ANTIMICROBIAL THERAPY OF COMMUNITY ACQUIRED PNEUMONIA IN CHILDREN (SCOUT-CAP).
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200006     HHSN272201300016I     NIAIDDMIDNIHAI2012144  
Friday, May 26, 2017
$1,278,322.00
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

C: DELIVERY ORDER
IGF::OT::IGF VACCINE AND TREATMENT EVALUATION UNITS
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200012     HHSN272201300016I     NIAIDDMIDNIHAI2012144  
Thursday, May 18, 2017
$0.00
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

B: IDC
IGF::OT::IGF AWARD OF VACCINE AND TREATMENT EVALUATION UNITS (VTEU) IDIQ CONTRACT, PERIOD OF PERFORMANCE OF SEPTEMBER 16, 2013 THROUGH SEPTEMBER 15, 2023.
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN272201300016I     NIAIDDMIDNIHAI2012144  
Wednesday, April 19, 2017
($61,766.23)
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

C: DELIVERY ORDER
IGF::OT::IGF VTEU 13-0034.C1.0015
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200002     HHSN272201300016I     NIAIDDMIDNIHAI2012144  
Thursday, March 23, 2017
$3,164,456.00
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

D: DEFINITIVE CONTRACT
VACCINE AND EVALUATION TREATMENT UNITS (VTEUS): EVALUATION OF CONTROL MEASURES FOR DISEASES OTHER THAN AIDS.
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN272200800006C  
Tuesday, March 21, 2017
$0.00
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

C: DELIVERY ORDER
IGF::OT::IGF A RANDOMIZED TRIAL TO EVALUATE SHORT COURSE VS. STANDARD COURSE OUTPATIENT BETA-LACTAM ANTIMICROBIAL THERAPY OF COMMUNITY ACQUIRED PNEUMONIA IN CHILDREN (SCOUT-CAP).
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200006     HHSN272201300016I     NIAIDDMIDNIHAI2012144  
Tuesday, March 14, 2017
$76,000.00
8000: National Aeronautics and Space Administration
80NSSC: NASA SHARED SERVICES CENTER

G: GRANT FOR RESEARCH
THE SUCCESSFUL DIASPORA OF HUMANS INTO DEEP SPACE REQUIRES AN UNDERSTANDING OF THE RISK OF DEEP SPACE RADIATION EXPOSURE ON SHORT AND LONG TERM HEALTH OUTCOMES, INCLUDING RISKS TO THE CENTRAL NERVOUS SYSTEM (CNS). ASSESSING CNS RISK MUST CONSIDER THE IMPACT OF DEEP SPACE RADIATION ON THE BEHAVIOR OF LATENT NEUROTROPIC INFECTIOUS AGENTS THAT RESIDE WITHIN THE HUMAN CNS. HERPES SIMPLEX VIRUS (HSV) IS AMONG THE MOST WIDESPREAD AGENT IN THIS CATEGORY, PERMANENTLY INFECTING THE NERVOUS SYSTEMS OF MORE THAN 80% OF THE GLOBAL POPULATION. LATENT HSV CANNOT BE ELIMINATED FROM THE NERVOUS SYSTEM AND THERE IS NO VACCINE TO PREVENT INFECTION. THUS FOR THE FORESEEABLE FUTURE, HUMANS TRAVELING INTO DEEP SPACE WILL HARBOR THIS AND OTHER ALPHA-HERPESVIRUSES. WHILE UNCONTROLLED HSV REPLICATION IN THE CNS RESULTS IN OFTEN FATAL ENCEPHALITIS, THIS VIRUS ALSO HAS THE CAPACITY TO PROMOTE CHRONIC INFLAMMATION AND NEURODEGENERATION. INDEED THERE IS SUBSTANTIAL EVIDENCE THAT IN COMBINATION WITH GENETIC RISK FACTORS, HSV INFECTION IN THE CNS FURTHER INCREASES THE PROBABILITY OF DEVELOPING ALZHEIMER S DISEASE. IN THIS PRO-POSAL, THE EFFECTS OF SIMULATED DEEP SPACE RADIATION ON THE DEVELOPMENT OF CNS PATHOLOGY (REACTIVE LESIONS) AND THE IMPACT OF LATENT AND INDUCED IN VIVO REACTIVATION OF HSV INFECTION ON THE DEVELOPMENT OF CNS PATHOLOGY WILL BE DETERMINED TOGETHER WITH THE ROLE THAT HUMAN APOE ALLELES PLAY IN THESE PROCESSES. WE WILL EMPLOY OUR WELL CHARACTERIZED MOUSE MODEL OF HSV LATENCY AND IN VIVO REACTIVATION IN COMBINATION WITH QUANTITATIVE MEASURES OF REACTIVE LESIONS IN THE CNS TO DETERMINE THE EFFECT OF SIMULATED DEEP SPACE RADIATION ON HSV MEDIATED CNS DAMAGE. THE ACUTE STAGE OF INFECTION WILL BE MONITORED USING OUR STANDARD APPROACHES INCLUDING QUANTITATIVE EVALUATION OF INFECTIOUS VIRUS TITERS. LATENT INFECTION IN THE TRIGEMINAL GANGLIA AND BRAIN WILL BE QUANTIFIED AT 30-40 DAYS POSTINFECTION (PI) USING OUR QUANTITATIVE REAL TIME PCR ASSAY FOR THE VIRAL GENOME. SPONTANEOUS AND INDUCED EXIT FROM LATENCY WILL BE QUANTIFIED AT THE SINGLE NEURON LEVEL USING OUR WHOLE TG IMMUNOHISTOCHEMICAL ASSAY. THIS APPROACH PERMITS US TO IDENTIFY EVEN A SINGLE POSITIVE NEURON IN GROUPS OF GANGLIA. VIRAL REACTIVATION (PRODUCTION OF INFECTIOUS VIRUS) WILL BE EVALUATED USING OUR STANDARD ASSAY. REACTIVATION WILL BE INDUCED USING OUR WELL-ESTABLISHED HYPERTHERMIC STRESS PROCEDURE (TEMPERATURE OF THE MICE IS RAISED TO 42.5 C FOR 10 MINUTES). WE HAVE SHOWN AND PUBLISHED THAT THIS PROCEDURE RELIABLY INDUCES VIRAL REACTIVATION AND CAN BE REPEATEDLY EMPLOYED TWO TIMES PER WEEK FOR PERIODS OF UP TO AT LEAST ONE YEAR PI. WE HAVE DETERMINED THE REPEATED REACTIVATION STRESS OF C57BL/6 MICE RESULTS IN REACTIVE ASTROCYTIC LESIONS IN THE CNS OF HSV INFECTED BUT NOT IN UNINFECTED MICE. INTERESTINGLY THIS DAMAGE IS MUCH MORE EXTENSIVE IN MICE THAT EXPRESS THE HUMAN APOE4 ALLELE OR IN IL10 KNOCK OUT MICE. THIS SUGGESTS IMPORTANT RELEVANCE TO HUMAN BIOLOGY SINCE BOTH IL10 POLYMORPHISMS AND THE APOE4 ALLELE HAVE BEEN SHOWN TO BE ASSOCIATED WITH INCREASED RISK OF ACQUIRING ALZHEIMER S DISEASE . WE NOW PROPOSE TO COLLABORATE WITH RADIATION BIOLOGISTS AT NASA TO DETERMINE APPROPRIATE CONDITIONS TO SIMULATE DEEP SPACE RADIATION AND WE WILL QUANTIFY THE EFFECTS OF SUCH RADIATION ON CNS DAMAGE INDUCED BY REACTIVATION OF HSV LATENT INFECTIONS. SIGNIFICANCE: THE GOAL OF NASA S SPACE RADIATION RESEARCH IS TO ENABLE THE HUMAN EXPLORATION OF SPACE WITHIN ACCEPTABLE RISKS FROM SPACE RADIATION. IMPORTANTLY, THE PROPOSED STUDIES WILL DETERMINE THE INTEGRATED RISK OF THE INTERACTION OF GALACTIC COSMIC RADIATION WITH UNINFECTED AND LATENTLY INFECTED CNS. THE PREVALENCE OF HSV INFECTION AMONG HUMANS MAKES THIS A NEARLY UNAVOIDABLE ADDITIONAL FACTOR THAT COULD SIGNIFICANLTY HEIGHTEN THE RISK OF CNS DAMAGE UPON GCR EXPOSURE.
AR21: R&D- SPACE: SCIENCE/APPLICATIONS (BASIC RESEARCH)

  NNX13AO47G  
Thursday, March 2, 2017
$0.00
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

C: DELIVERY ORDER
IGF::OT::IGF; VTEU PROTOCOL SUB-STUDIES: PROTOCOL DEVELOPMENT, IMPLEMENTATION AND ASSAYS, PROTOCOL 16-0006 POP 09/20/2015 TO 12/31/2017
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200007     HHSN272201300016I     NIAIDDMIDNIHAI2012144  
Friday, February 24, 2017
$0.00
8000: National Aeronautics and Space Administration
80NSSC: NASA SHARED SERVICES CENTER

G: GRANT FOR RESEARCH
THE SUCCESSFUL DIASPORA OF HUMANS INTO DEEP SPACE REQUIRES AN UNDERSTANDING OF THE RISK OF DEEP SPACE RADIATION EXPOSURE ON SHORT AND LONG TERM HEALTH OUTCOMES, INCLUDING RISKS TO THE CENTRAL NERVOUS SYSTEM (CNS). ASSESSING CNS RISK MUST CONSIDER THE IMPACT OF DEEP SPACE RADIATION ON THE BEHAVIOR OF LATENT NEUROTROPIC INFECTIOUS AGENTS THAT RESIDE WITHIN THE HUMAN CNS. HERPES SIMPLEX VIRUS (HSV) IS AMONG THE MOST WIDESPREAD AGENT IN THIS CATEGORY, PERMANENTLY INFECTING THE NERVOUS SYSTEMS OF MORE THAN 80% OF THE GLOBAL POPULATION. LATENT HSV CANNOT BE ELIMINATED FROM THE NERVOUS SYSTEM AND THERE IS NO VACCINE TO PREVENT INFECTION. THUS FOR THE FORESEEABLE FUTURE, HUMANS TRAVELING INTO DEEP SPACE WILL HARBOR THIS AND OTHER ALPHA-HERPESVIRUSES. WHILE UNCONTROLLED HSV REPLICATION IN THE CNS RESULTS IN OFTEN FATAL ENCEPHALITIS, THIS VIRUS ALSO HAS THE CAPACITY TO PROMOTE CHRONIC INFLAMMATION AND NEURODEGENERATION. INDEED THERE IS SUBSTANTIAL EVIDENCE THAT IN COMBINATION WITH GENETIC RISK FACTORS, HSV INFECTION IN THE CNS FURTHER INCREASES THE PROBABILITY OF DEVELOPING ALZHEIMER S DISEASE. IN THIS PRO-POSAL, THE EFFECTS OF SIMULATED DEEP SPACE RADIATION ON THE DEVELOPMENT OF CNS PATHOLOGY (REACTIVE LESIONS) AND THE IMPACT OF LATENT AND INDUCED IN VIVO REACTIVATION OF HSV INFECTION ON THE DEVELOPMENT OF CNS PATHOLOGY WILL BE DETERMINED TOGETHER WITH THE ROLE THAT HUMAN APOE ALLELES PLAY IN THESE PROCESSES. WE WILL EMPLOY OUR WELL CHARACTERIZED MOUSE MODEL OF HSV LATENCY AND IN VIVO REACTIVATION IN COMBINATION WITH QUANTITATIVE MEASURES OF REACTIVE LESIONS IN THE CNS TO DETERMINE THE EFFECT OF SIMULATED DEEP SPACE RADIATION ON HSV MEDIATED CNS DAMAGE. THE ACUTE STAGE OF INFECTION WILL BE MONITORED USING OUR STANDARD APPROACHES INCLUDING QUANTITATIVE EVALUATION OF INFECTIOUS VIRUS TITERS. LATENT INFECTION IN THE TRIGEMINAL GANGLIA AND BRAIN WILL BE QUANTIFIED AT 30-40 DAYS POSTINFECTION (PI) USING OUR QUANTITATIVE REAL TIME PCR ASSAY FOR THE VIRAL GENOME. SPONTANEOUS AND INDUCED EXIT FROM LATENCY WILL BE QUANTIFIED AT THE SINGLE NEURON LEVEL USING OUR WHOLE TG IMMUNOHISTOCHEMICAL ASSAY. THIS APPROACH PERMITS US TO IDENTIFY EVEN A SINGLE POSITIVE NEURON IN GROUPS OF GANGLIA. VIRAL REACTIVATION (PRODUCTION OF INFECTIOUS VIRUS) WILL BE EVALUATED USING OUR STANDARD ASSAY. REACTIVATION WILL BE INDUCED USING OUR WELL-ESTABLISHED HYPERTHERMIC STRESS PROCEDURE (TEMPERATURE OF THE MICE IS RAISED TO 42.5 C FOR 10 MINUTES). WE HAVE SHOWN AND PUBLISHED THAT THIS PROCEDURE RELIABLY INDUCES VIRAL REACTIVATION AND CAN BE REPEATEDLY EMPLOYED TWO TIMES PER WEEK FOR PERIODS OF UP TO AT LEAST ONE YEAR PI. WE HAVE DETERMINED THE REPEATED REACTIVATION STRESS OF C57BL/6 MICE RESULTS IN REACTIVE ASTROCYTIC LESIONS IN THE CNS OF HSV INFECTED BUT NOT IN UNINFECTED MICE. INTERESTINGLY THIS DAMAGE IS MUCH MORE EXTENSIVE IN MICE THAT EXPRESS THE HUMAN APOE4 ALLELE OR IN IL10 KNOCK OUT MICE. THIS SUGGESTS IMPORTANT RELEVANCE TO HUMAN BIOLOGY SINCE BOTH IL10 POLYMORPHISMS AND THE APOE4 ALLELE HAVE BEEN SHOWN TO BE ASSOCIATED WITH INCREASED RISK OF ACQUIRING ALZHEIMER S DISEASE . WE NOW PROPOSE TO COLLABORATE WITH RADIATION BIOLOGISTS AT NASA TO DETERMINE APPROPRIATE CONDITIONS TO SIMULATE DEEP SPACE RADIATION AND WE WILL QUANTIFY THE EFFECTS OF SUCH RADIATION ON CNS DAMAGE INDUCED BY REACTIVATION OF HSV LATENT INFECTIONS. SIGNIFICANCE: THE GOAL OF NASA S SPACE RADIATION RESEARCH IS TO ENABLE THE HUMAN EXPLORATION OF SPACE WITHIN ACCEPTABLE RISKS FROM SPACE RADIATION. IMPORTANTLY, THE PROPOSED STUDIES WILL DETERMINE THE INTEGRATED RISK OF THE INTERACTION OF GALACTIC COSMIC RADIATION WITH UNINFECTED AND LATENTLY INFECTED CNS. THE PREVALENCE OF HSV INFECTION AMONG HUMANS MAKES THIS A NEARLY UNAVOIDABLE ADDITIONAL FACTOR THAT COULD SIGNIFICANLTY HEIGHTEN THE RISK OF CNS DAMAGE UPON GCR EXPOSURE.
AR21: R&D- SPACE: SCIENCE/APPLICATIONS (BASIC RESEARCH)

  NNX13AO47G  
Tuesday, February 14, 2017
($5,330.75)
3600: Department of Veterans Affairs
36C539: 539-CINCINNATI (00539)

B: PURCHASE ORDER
TRAINING APPLICATION IGF::OT::IGF
U008: EDUCATION/TRAINING- TRAINING/CURRICULUM DEVELOPMENT

  VA25015P1091  
Tuesday, February 14, 2017
$0.00
7500: Department of Health and Human Services
75D301: CDC OFFICE OF ACQUISITION SERVICES

B: PURCHASE ORDER
IGF::OT::IGF ANTIGEN TESTING
Q301: MEDICAL- LABORATORY TESTING

  HHSD2002015M63224P     2015Q17298  
Monday, February 6, 2017
$0.00
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

B: IDC
IGF::OT::IGF THE PURPOSE OF THIS MODIFICATION IS TO REVISE VARIOUS ARTICLES AND CLAUSES IN ORDER TO INCORPORATE CHANGES REQUIRED BY LAW, REGULATION, AND POLICY.
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN272201300016I     NIAIDDMIDNIHAI2012144  
Monday, February 6, 2017
($3,138.77)
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

C: DELIVERY ORDER
IGF::OT::IGF; 1300016I CINCINNATI CHILDRENS HOSPITAL; VTEU; CLOSEOUT
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200005     HHSN272201300016I     NIAIDDMIDNIHAI2012144  
Monday, December 5, 2016
$0.00
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

B: IDC
IGF::OT::IGF THE PURPOSE OF THIS MODIFICATION IS TO ADD PAUL SPEARMAN, M.D. AS CO-PRINCIPAL INVESTIGATOR UNDER ARTICLE G.2. KEY PERSONNEL.
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN272201300016I     NIAIDDMIDNIHAI2012144  
Monday, November 21, 2016
($16,705.02)
7500: Department of Health and Human Services
75N940: NATIONAL INSTITUTES OF HEALTH NICHD

D: DEFINITIVE CONTRACT
FINAL_CLOSE_PROCESS -FINAL_CLOSE_PROCESS -
AN91: R&D- MEDICAL: OTHER (BASIC RESEARCH)

  HHSN275200900018C  
Thursday, November 17, 2016
$176,071.00
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

C: DELIVERY ORDER
IGF::OT::IGF OVERALL ADMINISTRATION, CLINICAL OPERATIONS SUPPORT AND CONCEPT AND PROTOCOL DEVELOPMENT, IMPLEMENTATION AND ASSAYS
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200010     HHSN272201300016I     FY.2017.A1B1C1D1.0048  
Monday, October 24, 2016
$0.00
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

C: DELIVERY ORDER
IGF::OT::IGF VACCINE AND TREATMENT EVALUATION UNITS
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200011     HHSN272201300016I     NIAIDDMIDNIHAI2012144  
Thursday, September 22, 2016
$0.00
7500: Department of Health and Human Services
75D301: CDC - PITTSBURG

C: DELIVERY ORDER
IGF::OT::IGF CISA CHILDERN'S HOSPITAL MEDICAL CENTER
AN46: R&D- MEDICAL: HEALTH SERVICES (MANAGEMENT/SUPPORT)

  HHSD2002012536610004     HHSD200201253661I  
Thursday, September 22, 2016
$643,450.00
7500: Department of Health and Human Services
75D301: CDC - PITTSBURG

D: DEFINITIVE CONTRACT
IGF::OT::IGF METAGENOMIC PREDICTORS
AB91: R&D- COMMUNITY SERVICE/DEVELOPMENT: OTHER (BASIC RESEARCH)

  HHSD200201691939C  
Tuesday, September 20, 2016
$512,034.00
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

C: DELIVERY ORDER
IGF::OT::IGF PROTOCOL DEVELOPMENT(BASE) AND PROTOCOL IMPLEMENTATION(OPTIONS 1-6) RELATIVE TO PROTOCOL 14-0112, A PHASE II DOUBLE-BLIND RANDOMIZED PLACEBO CONTROLLED TRIAL TO EVALUATE THE SAFETY, REACTOGENICITY, AND IMMUNOGENICITY OF ONE OR TWO DOSES OF M-001 FOLLOWED BY ONE OR TWO DOSES OF AN INFLUENZA A/H7N9 VACCINE IN HEALTHY VOLUNTEERS.
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200009     HHSN272201300016I     NIAIDDMIDNIHAI2012144  
Monday, September 19, 2016
$762,539.00
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

C: DELIVERY ORDER
IGF::OT::IGF VACCINE AND TREATMENT EVALUATION UNITS
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200011     HHSN272201300016I     NIAIDDMIDNIHAI2012144  
Friday, September 16, 2016
$39,256.00
7500: Department of Health and Human Services
75D301: CDC - PITTSBURG

C: DELIVERY ORDER
IGF::OT::IGF CISA CLINICAL CONSULT ACTIVITY
B537: SPECIAL STUDIES/ANALYSIS- MEDICAL/HEALTH

  HHSD2002012536610002     HHSD200201253661I  
Wednesday, September 14, 2016
$0.00
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

C: DELIVERY ORDER
IGF::OT::IGF A RANDOMIZED TRIAL TO EVALUATE SHORT COURSE VS. STANDARD COURSE OUTPATIENT BETA-LACTAM ANTIMICROBIAL THERAPY OF COMMUNITY ACQUIRED PNEUMONIA IN CHILDREN (SCOUT-CAP).
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200006     HHSN272201300016I     NIAIDDMIDNIHAI2012144  
Wednesday, September 14, 2016
$198,682.00
7500: Department of Health and Human Services
75D301: CDC - PITTSBURG

C: DELIVERY ORDER
IGF::OT::IGF CISA CHILDERN'S HOSPITAL MEDICAL CENTER
R499: SUPPORT- PROFESSIONAL: OTHER

  HHSD2002012536610003     HHSD200201253661I  
Tuesday, September 13, 2016
$141,087.00
7500: Department of Health and Human Services
75D301: CDC - PITTSBURG

C: DELIVERY ORDER
IGF::OT::IGF CISA CHILDERN'S HOSPITAL MEDICAL CENTER
AJ11: R&D- GENERAL SCIENCE/TECHNOLOGY: PHYSICAL SCIENCES (BASIC RESEARCH)

  HHSD2002012536610006     HHSD200201253661I  
Tuesday, September 6, 2016
($1,668,249.80)
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

D: DEFINITIVE CONTRACT
VACCINE AND EVALUATION TREATMENT UNITS (VTEUS): EVALUATION OF CONTROL MEASURES FOR DISEASES OTHER THAN AIDS.
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN272200800006C  
Thursday, August 25, 2016
$0.00
8000: National Aeronautics and Space Administration
80NSSC: NASA SHARED SERVICES CENTER

G: GRANT FOR RESEARCH
THE SUCCESSFUL DIASPORA OF HUMANS INTO DEEP SPACE REQUIRES AN UNDERSTANDING OF THE RISK OF DEEP SPACE RADIATION EXPOSURE ON SHORT AND LONG TERM HEALTH OUTCOMES, INCLUDING RISKS TO THE CENTRAL NERVOUS SYSTEM (CNS). ASSESSING CNS RISK MUST CONSIDER THE IMPACT OF DEEP SPACE RADIATION ON THE BEHAVIOR OF LATENT NEUROTROPIC INFECTIOUS AGENTS THAT RESIDE WITHIN THE HUMAN CNS. HERPES SIMPLEX VIRUS (HSV) IS AMONG THE MOST WIDESPREAD AGENT IN THIS CATEGORY, PERMANENTLY INFECTING THE NERVOUS SYSTEMS OF MORE THAN 80% OF THE GLOBAL POPULATION. LATENT HSV CANNOT BE ELIMINATED FROM THE NERVOUS SYSTEM AND THERE IS NO VACCINE TO PREVENT INFECTION. THUS FOR THE FORESEEABLE FUTURE, HUMANS TRAVELING INTO DEEP SPACE WILL HARBOR THIS AND OTHER ALPHA-HERPESVIRUSES. WHILE UNCONTROLLED HSV REPLICATION IN THE CNS RESULTS IN OFTEN FATAL ENCEPHALITIS, THIS VIRUS ALSO HAS THE CAPACITY TO PROMOTE CHRONIC INFLAMMATION AND NEURODEGENERATION. INDEED THERE IS SUBSTANTIAL EVIDENCE THAT IN COMBINATION WITH GENETIC RISK FACTORS, HSV INFECTION IN THE CNS FURTHER INCREASES THE PROBABILITY OF DEVELOPING ALZHEIMER S DISEASE. IN THIS PRO-POSAL, THE EFFECTS OF SIMULATED DEEP SPACE RADIATION ON THE DEVELOPMENT OF CNS PATHOLOGY (REACTIVE LESIONS) AND THE IMPACT OF LATENT AND INDUCED IN VIVO REACTIVATION OF HSV INFECTION ON THE DEVELOPMENT OF CNS PATHOLOGY WILL BE DETERMINED TOGETHER WITH THE ROLE THAT HUMAN APOE ALLELES PLAY IN THESE PROCESSES. WE WILL EMPLOY OUR WELL CHARACTERIZED MOUSE MODEL OF HSV LATENCY AND IN VIVO REACTIVATION IN COMBINATION WITH QUANTITATIVE MEASURES OF REACTIVE LESIONS IN THE CNS TO DETERMINE THE EFFECT OF SIMULATED DEEP SPACE RADIATION ON HSV MEDIATED CNS DAMAGE. THE ACUTE STAGE OF INFECTION WILL BE MONITORED USING OUR STANDARD APPROACHES INCLUDING QUANTITATIVE EVALUATION OF INFECTIOUS VIRUS TITERS. LATENT INFECTION IN THE TRIGEMINAL GANGLIA AND BRAIN WILL BE QUANTIFIED AT 30-40 DAYS POSTINFECTION (PI) USING OUR QUANTITATIVE REAL TIME PCR ASSAY FOR THE VIRAL GENOME. SPONTANEOUS AND INDUCED EXIT FROM LATENCY WILL BE QUANTIFIED AT THE SINGLE NEURON LEVEL USING OUR WHOLE TG IMMUNOHISTOCHEMICAL ASSAY. THIS APPROACH PERMITS US TO IDENTIFY EVEN A SINGLE POSITIVE NEURON IN GROUPS OF GANGLIA. VIRAL REACTIVATION (PRODUCTION OF INFECTIOUS VIRUS) WILL BE EVALUATED USING OUR STANDARD ASSAY. REACTIVATION WILL BE INDUCED USING OUR WELL-ESTABLISHED HYPERTHERMIC STRESS PROCEDURE (TEMPERATURE OF THE MICE IS RAISED TO 42.5 C FOR 10 MINUTES). WE HAVE SHOWN AND PUBLISHED THAT THIS PROCEDURE RELIABLY INDUCES VIRAL REACTIVATION AND CAN BE REPEATEDLY EMPLOYED TWO TIMES PER WEEK FOR PERIODS OF UP TO AT LEAST ONE YEAR PI. WE HAVE DETERMINED THE REPEATED REACTIVATION STRESS OF C57BL/6 MICE RESULTS IN REACTIVE ASTROCYTIC LESIONS IN THE CNS OF HSV INFECTED BUT NOT IN UNINFECTED MICE. INTERESTINGLY THIS DAMAGE IS MUCH MORE EXTENSIVE IN MICE THAT EXPRESS THE HUMAN APOE4 ALLELE OR IN IL10 KNOCK OUT MICE. THIS SUGGESTS IMPORTANT RELEVANCE TO HUMAN BIOLOGY SINCE BOTH IL10 POLYMORPHISMS AND THE APOE4 ALLELE HAVE BEEN SHOWN TO BE ASSOCIATED WITH INCREASED RISK OF ACQUIRING ALZHEIMER S DISEASE . WE NOW PROPOSE TO COLLABORATE WITH RADIATION BIOLOGISTS AT NASA TO DETERMINE APPROPRIATE CONDITIONS TO SIMULATE DEEP SPACE RADIATION AND WE WILL QUANTIFY THE EFFECTS OF SUCH RADIATION ON CNS DAMAGE INDUCED BY REACTIVATION OF HSV LATENT INFECTIONS. SIGNIFICANCE: THE GOAL OF NASA S SPACE RADIATION RESEARCH IS TO ENABLE THE HUMAN EXPLORATION OF SPACE WITHIN ACCEPTABLE RISKS FROM SPACE RADIATION. IMPORTANTLY, THE PROPOSED STUDIES WILL DETERMINE THE INTEGRATED RISK OF THE INTERACTION OF GALACTIC COSMIC RADIATION WITH UNINFECTED AND LATENTLY INFECTED CNS. THE PREVALENCE OF HSV INFECTION AMONG HUMANS MAKES THIS A NEARLY UNAVOIDABLE ADDITIONAL FACTOR THAT COULD SIGNIFICANLTY HEIGHTEN THE RISK OF CNS DAMAGE UPON GCR EXPOSURE.
AR21: R&D- SPACE: SCIENCE/APPLICATIONS (BASIC RESEARCH)

  NNX13AO47G  
Monday, August 8, 2016
($35,407.53)
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

C: DELIVERY ORDER
IGF::OT::IGF; 1300016I CINCINNATI CHILDRENS HOSPITAL; VTEU; TO A1B1C1D1.0026 BASE, EXERCISE OPTION 1, DEOBLIGATE REMAINING FUNDS ON THE BASE IN THE AMOUNT OF $122,995.53, CORRECT THE PERIOD OF PERFORMANCE THAT WAS LISTED IN THE ORIGINAL TASK ORDER AWARD, AND UPDATE ARTICLE G.4.
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200005     HHSN272201300016I     NIAIDDMIDNIHAI2012144  
Tuesday, July 26, 2016
($113,690.85)
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

C: DELIVERY ORDER
TO DE-OBLIGATE FUNDS, CLOSEOUT TASK ORDER (PHYSICALLY CLOSED) IGF::OT::IGF TO AWARD TASK A41 "MOUSE MODEL TESTING OF GSK GD-ALUM/MPL VACCINE"
AN11: R&D- MEDICAL: BIOMEDICAL (BASIC RESEARCH)

  HHSN27200002     HHSN272201000008I  
Monday, July 18, 2016
$337,619.00
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

C: DELIVERY ORDER
IGF::OT::IGF OVERALL ADMINISTRATION, CLINICAL OPERATIONS SUPPORT AND CONCEPT AND PROTOCOL DEVELOPMENT, IMPLEMENTATION AND ASSAYS
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200010     HHSN272201300016I     FY.2017.A1B1C1D1.0048  
Thursday, July 14, 2016
$0.00
7500: Department of Health and Human Services
75D301: CDC - PITTSBURG

B: PURCHASE ORDER
IGF::OT::IGF ANTIGEN TESTING
Q301: MEDICAL- LABORATORY TESTING

  HHSD2002015M63224P     2015Q17298  
Tuesday, July 12, 2016
$0.00
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

C: DELIVERY ORDER
IGF::OT::IGF A RANDOMIZED TRIAL TO EVALUATE SHORT COURSE VS. STANDARD COURSE OUTPATIENT BETA-LACTAM ANTIMICROBIAL THERAPY OF COMMUNITY ACQUIRED PNEUMONIA IN CHILDREN (SCOUT-CAP).
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200006     HHSN272201300016I     NIAIDDMIDNIHAI2012144  
Tuesday, July 12, 2016
$754,237.00
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

C: DELIVERY ORDER
TO EXERCISE TERM OPTION 1 WITH PERIOD OF PERFORMANCE 08/31/2016 TO 08/30/2017 IGF::OT::IGF
AN11: R&D- MEDICAL: BIOMEDICAL (BASIC RESEARCH)

  HHSN27200003     HHSN272201000008I  
Tuesday, June 28, 2016
$7,500.00
7500: Department of Health and Human Services
75N910: NIH NCI

B: PURCHASE ORDER
CINCINNATI CHILDREN'S HOSPITAL [16-043336] IGF::CL::IGF
Q301: MEDICAL- LABORATORY TESTING

  HHSN261201600428P  
Tuesday, April 12, 2016
($202,821.05)
7500: Department of Health and Human Services
75N97A: NATIONAL INSTITUTES OF HEALTH CIT

C: DELIVERY ORDER
IGF::OT::IGF VTEU - ADMINISTRATIVE AND OVERALL CLINICAL OPERATIONS SUPPORT, INCLUDING IDENTIFICATION AND REVIEW OF CONCEPT PROPOSALS
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200001     HHSN272201300016I     NIAIDDMIDNIHAI2012144  
Wednesday, March 30, 2016
($59,761.10)
7500: Department of Health and Human Services
00272: NIH, NIAID DEA OA OFC ACQUISITIONS

C: DELIVERY ORDER
IGF::OT::IGF VTEU ADMINISTRATIVE, CLINICAL OPERATIONS SUPPORT, CONCEPT PROPOSALS CENTER; VTEU; TASK A1; BIOD CAN 8470038; $363,731
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200004     HHSN272201300016I     NIAIDDMIDNIHAI2012144  
Friday, March 25, 2016
$168,776.00
7500: Department of Health and Human Services
00272: NIH, NIAID DEA OA OFC ACQUISITIONS

C: DELIVERY ORDER
IGF::OT::IGF A RANDOMIZED TRIAL TO EVALUATE SHORT COURSE VS. STANDARD COURSE OUTPATIENT BETA-LACTAM ANTIMICROBIAL THERAPY OF COMMUNITY ACQUIRED PNEUMONIA IN CHILDREN (SCOUT-CAP).
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200006     HHSN272201300016I     NIAIDDMIDNIHAI2012144  
Wednesday, March 23, 2016
($8,894.69)
7500: Department of Health and Human Services
00275: NIH, NICHD, OD OAM OFC ADMIN MGMT

D: DEFINITIVE CONTRACT
FINAL_CLOSE_PROCESS -FINAL_CLOSE_PROCESS -
AN91: R&D- MEDICAL: OTHER (BASIC RESEARCH)

  HHSN275200900018C  
Tuesday, February 23, 2016
$0.00
7500: Department of Health and Human Services
00272: NIH, NIAID DEA OA OFC ACQUISITIONS

C: DELIVERY ORDER
IGF::OT::IGF 1300016I CINCINNATI CHILDRENS HOSPITAL; VTEU; TASK ORDER C1; 09-0009.C1.0013; POP EXTENSION MOD, EXTEND TO 12/31/16.
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200003     HHSN272201300016I     NIAIDDMIDNIHAI2012144  
Thursday, February 18, 2016
$76,524.00
8000: National Aeronautics and Space Administration
NSSC0: NASA SHARED SERVICES CENTER

G: GRANT FOR RESEARCH
THE SUCCESSFUL DIASPORA OF HUMANS INTO DEEP SPACE REQUIRES AN UNDERSTANDING OF THE RISK OF DEEP SPACE RADIATION EXPOSURE ON SHORT AND LONG TERM HEALTH OUTCOMES, INCLUDING RISKS TO THE CENTRAL NERVOUS SYSTEM (CNS). ASSESSING CNS RISK MUST CONSIDER THE IMPACT OF DEEP SPACE RADIATION ON THE BEHAVIOR OF LATENT NEUROTROPIC INFECTIOUS AGENTS THAT RESIDE WITHIN THE HUMAN CNS. HERPES SIMPLEX VIRUS (HSV) IS AMONG THE MOST WIDESPREAD AGENT IN THIS CATEGORY, PERMANENTLY INFECTING THE NERVOUS SYSTEMS OF MORE THAN 80% OF THE GLOBAL POPULATION. LATENT HSV CANNOT BE ELIMINATED FROM THE NERVOUS SYSTEM AND THERE IS NO VACCINE TO PREVENT INFECTION. THUS FOR THE FORESEEABLE FUTURE, HUMANS TRAVELING INTO DEEP SPACE WILL HARBOR THIS AND OTHER ALPHA-HERPESVIRUSES. WHILE UNCONTROLLED HSV REPLICATION IN THE CNS RESULTS IN OFTEN FATAL ENCEPHALITIS, THIS VIRUS ALSO HAS THE CAPACITY TO PROMOTE CHRONIC INFLAMMATION AND NEURODEGENERATION. INDEED THERE IS SUBSTANTIAL EVIDENCE THAT IN COMBINATION WITH GENETIC RISK FACTORS, HSV INFECTION IN THE CNS FURTHER INCREASES THE PROBABILITY OF DEVELOPING ALZHEIMER S DISEASE. IN THIS PRO-POSAL, THE EFFECTS OF SIMULATED DEEP SPACE RADIATION ON THE DEVELOPMENT OF CNS PATHOLOGY (REACTIVE LESIONS) AND THE IMPACT OF LATENT AND INDUCED IN VIVO REACTIVATION OF HSV INFECTION ON THE DEVELOPMENT OF CNS PATHOLOGY WILL BE DETERMINED TOGETHER WITH THE ROLE THAT HUMAN APOE ALLELES PLAY IN THESE PROCESSES. WE WILL EMPLOY OUR WELL CHARACTERIZED MOUSE MODEL OF HSV LATENCY AND IN VIVO REACTIVATION IN COMBINATION WITH QUANTITATIVE MEASURES OF REACTIVE LESIONS IN THE CNS TO DETERMINE THE EFFECT OF SIMULATED DEEP SPACE RADIATION ON HSV MEDIATED CNS DAMAGE. THE ACUTE STAGE OF INFECTION WILL BE MONITORED USING OUR STANDARD APPROACHES INCLUDING QUANTITATIVE EVALUATION OF INFECTIOUS VIRUS TITERS. LATENT INFECTION IN THE TRIGEMINAL GANGLIA AND BRAIN WILL BE QUANTIFIED AT 30-40 DAYS POSTINFECTION (PI) USING OUR QUANTITATIVE REAL TIME PCR ASSAY FOR THE VIRAL GENOME. SPONTANEOUS AND INDUCED EXIT FROM LATENCY WILL BE QUANTIFIED AT THE SINGLE NEURON LEVEL USING OUR WHOLE TG IMMUNOHISTOCHEMICAL ASSAY. THIS APPROACH PERMITS US TO IDENTIFY EVEN A SINGLE POSITIVE NEURON IN GROUPS OF GANGLIA. VIRAL REACTIVATION (PRODUCTION OF INFECTIOUS VIRUS) WILL BE EVALUATED USING OUR STANDARD ASSAY. REACTIVATION WILL BE INDUCED USING OUR WELL-ESTABLISHED HYPERTHERMIC STRESS PROCEDURE (TEMPERATURE OF THE MICE IS RAISED TO 42.5 C FOR 10 MINUTES). WE HAVE SHOWN AND PUBLISHED THAT THIS PROCEDURE RELIABLY INDUCES VIRAL REACTIVATION AND CAN BE REPEATEDLY EMPLOYED TWO TIMES PER WEEK FOR PERIODS OF UP TO AT LEAST ONE YEAR PI. WE HAVE DETERMINED THE REPEATED REACTIVATION STRESS OF C57BL/6 MICE RESULTS IN REACTIVE ASTROCYTIC LESIONS IN THE CNS OF HSV INFECTED BUT NOT IN UNINFECTED MICE. INTERESTINGLY THIS DAMAGE IS MUCH MORE EXTENSIVE IN MICE THAT EXPRESS THE HUMAN APOE4 ALLELE OR IN IL10 KNOCK OUT MICE. THIS SUGGESTS IMPORTANT RELEVANCE TO HUMAN BIOLOGY SINCE BOTH IL10 POLYMORPHISMS AND THE APOE4 ALLELE HAVE BEEN SHOWN TO BE ASSOCIATED WITH INCREASED RISK OF ACQUIRING ALZHEIMER S DISEASE . WE NOW PROPOSE TO COLLABORATE WITH RADIATION BIOLOGISTS AT NASA TO DETERMINE APPROPRIATE CONDITIONS TO SIMULATE DEEP SPACE RADIATION AND WE WILL QUANTIFY THE EFFECTS OF SUCH RADIATION ON CNS DAMAGE INDUCED BY REACTIVATION OF HSV LATENT INFECTIONS. SIGNIFICANCE: THE GOAL OF NASA S SPACE RADIATION RESEARCH IS TO ENABLE THE HUMAN EXPLORATION OF SPACE WITHIN ACCEPTABLE RISKS FROM SPACE RADIATION. IMPORTANTLY, THE PROPOSED STUDIES WILL DETERMINE THE INTEGRATED RISK OF THE INTERACTION OF GALACTIC COSMIC RADIATION WITH UNINFECTED AND LATENTLY INFECTED CNS. THE PREVALENCE OF HSV INFECTION AMONG HUMANS MAKES THIS A NEARLY UNAVOIDABLE ADDITIONAL FACTOR THAT COULD SIGNIFICANLTY HEIGHTEN THE RISK OF CNS DAMAGE UPON GCR EXPOSURE.
AR21: R&D- SPACE: SCIENCE/APPLICATIONS (BASIC RESEARCH)

  NNX13AO47G  
Friday, February 12, 2016
$0.00
7500: Department of Health and Human Services
00272: NIH, NIAID DEA OA OFC ACQUISITIONS

B: IDC
CHANGE COR TO WILLIAM DOWLING ANIMAL MODELS OF INFECTIOUS DISEASES
AN11: R&D- MEDICAL: BIOMEDICAL (BASIC RESEARCH)

  HHSN272201000008I  
Wednesday, February 10, 2016
$0.00
3600: Department of Veterans Affairs
00539: 539-CINCINNATI

B: PURCHASE ORDER
TRAINING APPLICATION IGF::OT::IGF
U008: EDUCATION/TRAINING- TRAINING/CURRICULUM DEVELOPMENT

  VA25015P1091  
Wednesday, February 10, 2016
($300.00)
3600: Department of Veterans Affairs
00539: 539-CINCINNATI

B: PURCHASE ORDER
TRAINING SOFTWARE APPLICATION DEVELOPMENT IGF::OT::IGF
U008: EDUCATION/TRAINING- TRAINING/CURRICULUM DEVELOPMENT

  VA25014P1649  
Thursday, January 14, 2016
($0.14)
7500: Department of Health and Human Services
00272: NIH, NIAID DEA OA OFC ACQUISITIONS

D: DEFINITIVE CONTRACT
EVALUATION OF CONTROL MEASURES AGAINST DISEASES OTHER THAN AIDS (VTEUS)
AB93: R&D- COMMUNITY SERVICE/DEVELOPMENT: OTHER (ADVANCED DEVELOPMENT)

  00266200206D266025459  
Wednesday, January 13, 2016
$89,675.00
7500: Department of Health and Human Services
00272: NIH, NIAID DEA OA OFC ACQUISITIONS

C: DELIVERY ORDER
IGF::OT::IGF PROTOCOL DEVELOPMENT(BASE) AND PROTOCOL IMPLEMENTATION(OPTIONS 1-6) RELATIVE TO PROTOCOL 14-0112, A PHASE II DOUBLE-BLIND RANDOMIZED PLACEBO CONTROLLED TRIAL TO EVALUATE THE SAFETY, REACTOGENICITY, AND IMMUNOGENICITY OF ONE OR TWO DOSES OF M-001 FOLLOWED BY ONE OR TWO DOSES OF AN INFLUENZA A/H7N9 VACCINE IN HEALTHY VOLUNTEERS.
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200009     HHSN272201300016I     NIAIDDMIDNIHAI2012144  
Monday, January 11, 2016
$0.00
7500: Department of Health and Human Services
00272: NIH, NIAID DEA OA OFC ACQUISITIONS

B: IDC
ANIMAL MODELS OF INFECTIOUS DISEASES
AN11: R&D- MEDICAL: BIOMEDICAL (BASIC RESEARCH)

  HHSN272201000008I  
Wednesday, October 21, 2015
$0.00
7500: Department of Health and Human Services
00272: NIH, NIAID DEA OA OFC ACQUISITIONS

B: IDC
ANIMAL MODELS OF INFECTIOUS DISEASES
AN11: R&D- MEDICAL: BIOMEDICAL (BASIC RESEARCH)

  HHSN272201000008I  
Monday, October 19, 2015
$617,036.00
7500: Department of Health and Human Services
00272: NIH, NIAID DEA OA OFC ACQUISITIONS

C: DELIVERY ORDER
IGF::OT::IGF; 1300016I TO 0008-15-0064.C1.0039 INFLUENZA A/H5N8 VIRUS VACCINE TRIAL; BIOD CAN 8470038; $617,036 POP 10/19/2015 THROUGH 10/15/2017
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200008     HHSN272201300016I     NIAIDDMIDNIHAI2012144  
Wednesday, September 30, 2015
$0.00
7500: Department of Health and Human Services
00272: NIH, NIAID DEA OA OFC ACQUISITIONS

C: DELIVERY ORDER
IGF::OT::IGF 1300016I CINCINNATI CHILDRENS HOSPITAL; VTEU; TASK ORDER C1; 09-0009.C1.0013; POP MOD, EXTEND TO 3/31/16.
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200003     HHSN272201300016I     NIAIDDMIDNIHAI2012144  
Monday, September 28, 2015
$296,773.00
7500: Department of Health and Human Services
00200: DEPT OF HHS/CENTERS FOR DISEASE CONTROL

C: DELIVERY ORDER
IGF::OT::IGF CISA CHILDERN'S HOSPITAL MEDICAL CENTER
AN46: R&D- MEDICAL: HEALTH SERVICES (MANAGEMENT/SUPPORT)

  HHSD2002012536610004     HHSD200201253661I  
Monday, September 28, 2015
$116,500.00
7500: Department of Health and Human Services
00200: DEPT OF HHS/CENTERS FOR DISEASE CONTROL

C: DELIVERY ORDER
IGF::OT::IGF CISA CHILDERN'S HOSPITAL MEDICAL CENTER
AN91: R&D- MEDICAL: OTHER (BASIC RESEARCH)

  HHSD2002012536610005     HHSD200201253661I  
Thursday, September 24, 2015
$159,576.00
7500: Department of Health and Human Services
00200: DEPT OF HHS/CENTERS FOR DISEASE CONTROL

C: DELIVERY ORDER
IGF::OT::IGF CISA CHILDERN'S HOSPITAL MEDICAL CENTER
R499: SUPPORT- PROFESSIONAL: OTHER

  HHSD2002012536610003     HHSD200201253661I  
Monday, September 21, 2015
$0.00
7500: Department of Health and Human Services
00275: NIH, NICHD, OD OAM OFC ADMIN MGMT

D: DEFINITIVE CONTRACT
IGF::OT::IGF MAINTENANCE, ANALYSIS AND DISSEMINATION OF CMIND DATABASE
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN275201400002C  
Sunday, September 20, 2015
$200,000.00
7500: Department of Health and Human Services
00272: NIH, NIAID DEA OA OFC ACQUISITIONS

C: DELIVERY ORDER
IGF::OT::IGF; 1300016I CINCINNATI CHILDREN'S HOSPITAL MEDICALCENTER; VTEU;D1B1C1.0032 POP 09/20/2015 TO 04/14/2017
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200007     HHSN272201300016I     NIAIDDMIDNIHAI2012144  
Tuesday, September 15, 2015
$79,911.00
7500: Department of Health and Human Services
00272: NIH, NIAID DEA OA OFC ACQUISITIONS

C: DELIVERY ORDER
IGF::OT::IGF TO 06 14-0079.B1C1.0028--16
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200006     HHSN272201300016I     NIAIDDMIDNIHAI2012144  
Monday, August 31, 2015
$734,332.00
7500: Department of Health and Human Services
00272: NIH, NIAID DEA OA OFC ACQUISITIONS

C: DELIVERY ORDER
IGF::OT::IGF R&D- MEDICAL: BIOMEDICAL (BASIC RESEARCH)
AN11: R&D- MEDICAL: BIOMEDICAL (BASIC RESEARCH)

  HHSN27200003     HHSN272201000008I  
Thursday, August 27, 2015
$39,256.00
7500: Department of Health and Human Services
00200: DEPT OF HHS/CENTERS FOR DISEASE CONTROL

C: DELIVERY ORDER
IGF::OT::IGF CISA CLINICAL CONSULT ACTIVITY
B537: SPECIAL STUDIES/ANALYSIS- MEDICAL/HEALTH

  HHSD2002012536610002     HHSD200201253661I  
Tuesday, July 21, 2015
$0.00
7500: Department of Health and Human Services
00272: NIH, NIAID DEA OA OFC ACQUISITIONS

D: DEFINITIVE CONTRACT
TO UPDATE THE PERIOD OF PERFORMANCE FOR VARIOUS OPTIONS AGAINST THE VACCINE AND EVALUATION TREATMENT UNITS (VTEUS): EVALUATION OF CONTROL MEASURES FOR DISEASES OTHER THAN AIDS.
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN272200800006C  
Tuesday, July 14, 2015
$31,781.36
7500: Department of Health and Human Services
00200: DEPT OF HHS/CENTERS FOR DISEASE CONTROL

B: PURCHASE ORDER
IGF::OT::IGF ANTIGEN TESTING
Q301: MEDICAL- LABORATORY TESTING

  HHSD2002015M63224P     2015Q17298  
Monday, July 13, 2015
$336,281.00
7500: Department of Health and Human Services
00272: NIH, NIAID DEA OA OFC ACQUISITIONS

C: DELIVERY ORDER
IGF::OT::IGF; 1300016I CINCINNATI CHILDRENS HOSPITAL; VTEU; TO A1B1C1D1.0026 BASE
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200005     HHSN272201300016I     NIAIDDMIDNIHAI2012144  
Monday, June 22, 2015
$328,435.00
8000: National Aeronautics and Space Administration
NSSC0: NASA SHARED SERVICES CENTER

G: GRANT FOR RESEARCH
THE SUCCESSFUL DIASPORA OF HUMANS INTO DEEP SPACE REQUIRES AN UNDERSTANDING OF THE RISK OF DEEP SPACE RADIATION EXPOSURE ON SHORT AND LONG TERM HEALTH OUTCOMES, INCLUDING RISKS TO THE CENTRAL NERVOUS SYSTEM (CNS). ASSESSING CNS RISK MUST CONSIDER THE IMPACT OF DEEP SPACE RADIATION ON THE BEHAVIOR OF LATENT NEUROTROPIC INFECTIOUS AGENTS THAT RESIDE WITHIN THE HUMAN CNS. HERPES SIMPLEX VIRUS (HSV) IS AMONG THE MOST WIDESPREAD AGENT IN THIS CATEGORY, PERMANENTLY INFECTING THE NERVOUS SYSTEMS OF MORE THAN 80% OF THE GLOBAL POPULATION. LATENT HSV CANNOT BE ELIMINATED FROM THE NERVOUS SYSTEM AND THERE IS NO VACCINE TO PREVENT INFECTION. THUS FOR THE FORESEEABLE FUTURE, HUMANS TRAVELING INTO DEEP SPACE WILL HARBOR THIS AND OTHER ALPHA-HERPESVIRUSES. WHILE UNCONTROLLED HSV REPLICATION IN THE CNS RESULTS IN OFTEN FATAL ENCEPHALITIS, THIS VIRUS ALSO HAS THE CAPACITY TO PROMOTE CHRONIC INFLAMMATION AND NEURODEGENERATION. INDEED THERE IS SUBSTANTIAL EVIDENCE THAT IN COMBINATION WITH GENETIC RISK FACTORS, HSV INFECTION IN THE CNS FURTHER INCREASES THE PROBABILITY OF DEVELOPING ALZHEIMER S DISEASE. IN THIS PRO-POSAL, THE EFFECTS OF SIMULATED DEEP SPACE RADIATION ON THE DEVELOPMENT OF CNS PATHOLOGY (REACTIVE LESIONS) AND THE IMPACT OF LATENT AND INDUCED IN VIVO REACTIVATION OF HSV INFECTION ON THE DEVELOPMENT OF CNS PATHOLOGY WILL BE DETERMINED TOGETHER WITH THE ROLE THAT HUMAN APOE ALLELES PLAY IN THESE PROCESSES. WE WILL EMPLOY OUR WELL CHARACTERIZED MOUSE MODEL OF HSV LATENCY AND IN VIVO REACTIVATION IN COMBINATION WITH QUANTITATIVE MEASURES OF REACTIVE LESIONS IN THE CNS TO DETERMINE THE EFFECT OF SIMULATED DEEP SPACE RADIATION ON HSV MEDIATED CNS DAMAGE. THE ACUTE STAGE OF INFECTION WILL BE MONITORED USING OUR STANDARD APPROACHES INCLUDING QUANTITATIVE EVALUATION OF INFECTIOUS VIRUS TITERS. LATENT INFECTION IN THE TRIGEMINAL GANGLIA AND BRAIN WILL BE QUANTIFIED AT 30-40 DAYS POSTINFECTION (PI) USING OUR QUANTITATIVE REAL TIME PCR ASSAY FOR THE VIRAL GENOME. SPONTANEOUS AND INDUCED EXIT FROM LATENCY WILL BE QUANTIFIED AT THE SINGLE NEURON LEVEL USING OUR WHOLE TG IMMUNOHISTOCHEMICAL ASSAY. THIS APPROACH PERMITS US TO IDENTIFY EVEN A SINGLE POSITIVE NEURON IN GROUPS OF GANGLIA. VIRAL REACTIVATION (PRODUCTION OF INFECTIOUS VIRUS) WILL BE EVALUATED USING OUR STANDARD ASSAY. REACTIVATION WILL BE INDUCED USING OUR WELL-ESTABLISHED HYPERTHERMIC STRESS PROCEDURE (TEMPERATURE OF THE MICE IS RAISED TO 42.5 C FOR 10 MINUTES). WE HAVE SHOWN AND PUBLISHED THAT THIS PROCEDURE RELIABLY INDUCES VIRAL REACTIVATION AND CAN BE REPEATEDLY EMPLOYED TWO TIMES PER WEEK FOR PERIODS OF UP TO AT LEAST ONE YEAR PI. WE HAVE DETERMINED THE REPEATED REACTIVATION STRESS OF C57BL/6 MICE RESULTS IN REACTIVE ASTROCYTIC LESIONS IN THE CNS OF HSV INFECTED BUT NOT IN UNINFECTED MICE. INTERESTINGLY THIS DAMAGE IS MUCH MORE EXTENSIVE IN MICE THAT EXPRESS THE HUMAN APOE4 ALLELE OR IN IL10 KNOCK OUT MICE. THIS SUGGESTS IMPORTANT RELEVANCE TO HUMAN BIOLOGY SINCE BOTH IL10 POLYMORPHISMS AND THE APOE4 ALLELE HAVE BEEN SHOWN TO BE ASSOCIATED WITH INCREASED RISK OF ACQUIRING ALZHEIMER S DISEASE . WE NOW PROPOSE TO COLLABORATE WITH RADIATION BIOLOGISTS AT NASA TO DETERMINE APPROPRIATE CONDITIONS TO SIMULATE DEEP SPACE RADIATION AND WE WILL QUANTIFY THE EFFECTS OF SUCH RADIATION ON CNS DAMAGE INDUCED BY REACTIVATION OF HSV LATENT INFECTIONS. SIGNIFICANCE: THE GOAL OF NASA S SPACE RADIATION RESEARCH IS TO ENABLE THE HUMAN EXPLORATION OF SPACE WITHIN ACCEPTABLE RISKS FROM SPACE RADIATION. IMPORTANTLY, THE PROPOSED STUDIES WILL DETERMINE THE INTEGRATED RISK OF THE INTERACTION OF GALACTIC COSMIC RADIATION WITH UNINFECTED AND LATENTLY INFECTED CNS. THE PREVALENCE OF HSV INFECTION AMONG HUMANS MAKES THIS A NEARLY UNAVOIDABLE ADDITIONAL FACTOR THAT COULD SIGNIFICANLTY HEIGHTEN THE RISK OF CNS DAMAGE UPON GCR EXPOSURE.
AR21: R&D- SPACE: SCIENCE/APPLICATIONS (BASIC RESEARCH)

  NNX13AO47G  
Monday, May 18, 2015
$853,675.00
7500: Department of Health and Human Services
00272: NIH, NIAID DEA OA OFC ACQUISITIONS

D: DEFINITIVE CONTRACT
TO FUND COST OVERRUNS ON OPTIONS 6E-11-0034 AND OPTION 8C-12-0023 AGAINST THE VACCINE AND EVALUATION TREATMENT UNITS (VTEUS): EVALUATION OF CONTROL MEASURES FOR DISEASES OTHER THAN AIDS.
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN272200800006C  
Wednesday, April 22, 2015
$7,682.00
9700: Department of Defense
N00183: NAVAL MEDICAL CENTER PORTSMOUTH VA

B: PURCHASE ORDER
IGF::OT::IGF LABORATORY TESTS NOT PERFORMED AT THIS FACILITY
Q301: MEDICAL- LABORATORY TESTING

  N0018315P1417  
Monday, April 20, 2015
($34,291.38)
7500: Department of Health and Human Services
00272: NIH, NIAID DEA OA OFC ACQUISITIONS

D: DEFINITIVE CONTRACT
THE PURPOSE OF THIS ACTION IS TO ADMINISTRATIVELY DEOBLIGATE FUNDS THERE IS NO ACTION REQUIRED BY THE CONTRACTOR
AN11: R&D- MEDICAL: BIOMEDICAL (BASIC RESEARCH)

  00266200105D266015438  
Tuesday, February 24, 2015
$28,601.75
3600: VETERANS AFFAIRS, DEPARTMENT OF
00539: 539-CINCINNATI

PO Purchase Order
TRAINING APPLICATION IGF::OT::IGF
U008: EDUCATION/TRAINING- TRAINING/CURRICULUM DEVELOPMENT

  VA25015P1091  
Friday, January 30, 2015
$0.00
7500: HEALTH AND HUMAN SERVICES, DEPARTMENT OF
00272: NIH, NIAID DEA OA OFC ACQUISITIONS

DCA Definitive Contract
THE PURPOSE OF THIS ACTION IS TO ADMINISTRATIVELY CHANGE THE CPD IN NBS. THERE IS NO ACTION REQUIRED BY THE CONTRACTOR
AN11: R&D- MEDICAL: BIOMEDICAL (BASIC RESEARCH)

  00266200105D266015438  
Friday, January 30, 2015
$5,098.00
7500: HEALTH AND HUMAN SERVICES, DEPARTMENT OF
00269: NIH, CC, OD OCOO OA OFC ACQUISITIONS

PO Purchase Order
IGF::OT::IGF MEDICAL- LABORATORY TESTING
Q301: MEDICAL- LABORATORY TESTING

  HHSN269201500338PC  
Friday, January 16, 2015
$135,000.00
7500: Department of Health and Human Services
00200: DEPT OF HHS/CENTERS FOR DISEASE CONTROL

B: PURCHASE ORDER
DATA ANALYSIS AND REPORT FOR EV D-68; IGF::OT::IGF
B599: SPECIAL STUDIES/ANALYSIS- OTHER

  HHSD2002015M61640P     2015Q16896  
Thursday, November 20, 2014
$0.00
7500: HEALTH AND HUMAN SERVICES, DEPARTMENT OF
00272: NIH, NIAID DEA OA OFC ACQUISITIONS

IDC Indefinite Delivery Contract
IGF::OT::IGF THE PURPOSE OF THIS MODIFICATION IS TO UPDATE VARIOUS CONTRACT CLAUSES AND ARTICLES.
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN272201300016I     NIAIDDMIDNIHAI2012144  
Saturday, September 27, 2014
$499,986.00
7500: Department of Health and Human Services
00200: DEPT OF HHS/CENTERS FOR DISEASE CONTROL

C: DELIVERY ORDER
IGF::OT::IGF CISA CHILDERN'S HOSPITAL MEDICAL CENTER
R499: SUPPORT- PROFESSIONAL: OTHER

  HHSD2002012536610003     HHSD200201253661I  
Friday, September 26, 2014
$239,000.00
7500: HEALTH AND HUMAN SERVICES, DEPARTMENT OF
00275: NIH, NICHD, OD OAM OFC ADMIN MGMT

DCA Definitive Contract
IGF::OT::IGF MAINTENANCE, ANALYSIS AND DISSEMINATION OF CMIND DATABASE
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN275201400002C  
Wednesday, September 10, 2014
$363,731.00
7500: HEALTH AND HUMAN SERVICES, DEPARTMENT OF
00272: NIH, NIAID DEA OA OFC ACQUISITIONS

DO Delivery Order
IGF::OT::IGF 1300016I CINCINNATI CHILDRENS HOSPITAL MEDICAL CENTER; VTEU; TASK A1; BIOD CAN 8470038; $363,731
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200004     HHSN272201300016I     NIAIDDMIDNIHAI2012144  
Tuesday, September 9, 2014
$1,805,728.00
7500: Department of Health and Human Services
00272: NIH, NIAID DEA OA OFC ACQUISITIONS

D: DEFINITIVE CONTRACT
TO FUND COST OVERRUNS ON OPTIONS 6E-11-0034 AND OPTION 8C-12-0023 AGAINST THE VACCINE AND EVALUATION TREATMENT UNITS (VTEUS): EVALUATION OF CONTROL MEASURES FOR DISEASES OTHER THAN AIDS.
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN272200800006C  
Wednesday, August 27, 2014
$0.00
7500: HEALTH AND HUMAN SERVICES, DEPARTMENT OF
00273: NIH, NIEHS, OD OM OA OFC ACQUISITIONS

PO Purchase Order
IGF::OT::IGF MYOVISION STUDY
R499: SUPPORT- PROFESSIONAL: OTHER

  HHSN273201300196P  
Friday, August 22, 2014
$2,080.00
3600: VETERANS AFFAIRS, DEPARTMENT OF
00539: 539-CINCINNATI

PO Purchase Order
TRAINING SOFTWARE APPLICATION DEVELOPMENT IGF::OT::IGF
U008: EDUCATION/TRAINING- TRAINING/CURRICULUM DEVELOPMENT

  VA25014P1649  
Friday, August 15, 2014
$600,083.00
7500: HEALTH AND HUMAN SERVICES, DEPARTMENT OF
00272: NIH, NIAID DEA OA OFC ACQUISITIONS

DO Delivery Order
IGF::OT::IGF 1300016I CINCINNATI CHILDRENS HOSPITAL; VTEU; TASK ORDER C1; 09-0009.C1.0013; BIOD CAN 8470038; $600,083
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200003     HHSN272201300016I     NIAIDDMIDNIHAI2012144  
Thursday, August 7, 2014
$832,511.00
7500: HEALTH AND HUMAN SERVICES, DEPARTMENT OF
00272: NIH, NIAID DEA OA OFC ACQUISITIONS

DO Delivery Order
IGF::OT::IGF VTEU 13-0034.C1.0015
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200002     HHSN272201300016I     NIAIDDMIDNIHAI2012144